Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 20th Preview)
-
Regulatory approval: liquid biopsy expansion
Guardant Health’s upgraded Guardant360 Liquid CDx won FDA approval, expanding the blood-based, tumor-informed genomic/epigenomic test’s clinical reach. The new assay evaluates a 100-fold larger genomic footprint than the prior Guardant360 Liquid CDx version and transfers the seven existing companion-diagnostic indications to the updated platform. The test is intended to guide treatment decisions in advanced cancer, leveraging circulating tumor DNA (ctDNA) and epigenomics from a single blood draw. Guardant says the analytical sensitivity is severalfold higher, aiming to capture tumor signals that may be missed by genomics alone. Helmy Eltoukhy, chairman and co-CEO of Guardant, framed the approval as convergence of genomics, epigenomics, AI, and data from more than 1 million patients tested. The approval also has near-term commercial implications for Guardant’s Advanced Diagnostic Laboratory status and reimbursement dynamics.
-
Oncology diagnostics & MRD coverage
Personalis said CMS expanded Medicare coverage for its NeXT Personal minimal residual disease (MRD) test to include monitoring response to neoadjuvant therapy in stages II to III triple-negative or HER2-positive breast cancer. The decision cites evidence from the PREDICT-DNA prospective study and marks the fourth Medicare coverage determination for the whole-genome sequencing-based, tumor-informed assay. The company previously secured coverage for immunotherapy monitoring across late-stage solid tumors, plus recurrence monitoring in stages II to III breast cancer and stages I to III non-small cell lung cancer. Personalis positioned the latest approval as moving NeXT Personal into active treatment management decisions across the breast cancer continuum. Shares rose nearly 9% in premarket trading following the CMS update, underscoring investor focus on payor adoption as MRD testing shifts toward routine clinical workflows.
-
Ebola response: WHO escalates Bundibugyo outbreak
WHO declared the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo a public health emergency of international concern, escalating an outbreak now spreading across DRC and reaching Uganda. The WHO cited rapid spread indicators, suspected case clusters, and significant uncertainties about the true extent of transmission. The Bundibugyo species currently has no licensed vaccine or antiviral treatment, which has pushed attention toward development programs including mRNA candidates that are not yet ready for deployment. Public health officials and infectious-disease experts emphasized that while the situation is serious, the risk of a pandemic-level threat remains low. Clinical and operational constraints—especially in remote conflict-affected regions—are limiting access for health care workers and complicating containment, according to officials and stakeholders in the response ecosystem.
-
Biopharma AI dealmaking: data platforms deepen
Collaborative Drug Discovery expanded its AI collaboration with Eli Lilly by planning tighter integration of Lilly TuneLab predictive models into CDD Vault workflows. The agreement targets ADMET modeling inside CDD Vault and sets up broader model integration across the platform’s core and AI modules for participating biopharma companies. CDD framed the partnership as an extension of its web-based collaboration approach, enabling secure access to Lilly’s proprietary-trained models while keeping analysis and experimentation inside a protected environment. The companies said the models are designed to fit naturally into experimental and computational workflows. The move underscores how major pharma is turning internal AI assets into partner-facing toolkits, as biotechs look to accelerate target and lead optimization using curated, high-quality predictive models.
-
AI in oncology prognosis: multimodal models
Researchers published a multimodal AI framework intended to improve breast cancer prognostication, combining multiple data sources into a single predictive approach. The study, led by Witowski, Zeng, and Cappadona and published in Nature Communications, aims to integrate diverse inputs into a prognosis-oriented model designed for clinical applicability. A separate AI approach highlighted by HELIX focuses on RNA splicing prediction by integrating genomic sequence features with tissue-specific RNA binding protein (RBP) expression. While more mechanistic than purely prognostic, the splicing model provides a foundation for understanding disease-associated isoform shifts that can influence tumor behavior. Together, the updates reflect a push to move AI beyond single-modality imaging or genomics, toward multi-layer biological context for oncology decision-making and precision medicine research.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.